Radiosensitization of Hs-766T pancreatic tumor xenografts in mice dosed with dodecafluoropentane nano-emulsion-preliminary findings

Journal of Biomedical Nanotechnology

Volumn 11, Issue 2, 2015, Pages 274-281

  Johnson, Jennifer L H ^a   Leos, Rafael A ^a,d   Baker, Amanda F ^b   Unger, Evan C ^a,c  

^a NuvOx Pharma LLC   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Ventana Medical Systems   (United States)

Author keywords

Dodecafluoropentane; Nano emulsion; Oxygen therapeutic; Radiation; Radioensitization; Tumor hypoxia

Indexed keywords

BIOLOGICAL MATERIALS; EMULSIFICATION; EMULSIONS; HEAT RADIATION; MAMMALS; OXYGEN; RADIATION; RADIOTHERAPY;

DODECAFLUOROPENTANE; NANOEMULSION; RADIATION RESPONSE; RADIATION SENSITIZERS; RADIATION TREATMENTS; RADIO-SENSITIZATION; RADIOENSITIZATION; TUMOR HYPOXIA;

TUMORS;

CARBOGEN; ENDOTOXIN; NVX 108; OXYGEN; PERFLUOROPENTANE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; EMULSION; FLUOROCARBON; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HYPOXIA; MOUSE; NANOEMULSION; NONHUMAN; OXYGEN TENSION; PANCREAS TUMOR; PARTICLE SIZE; PH; RADIATION DOSE; RADIOSENSITIZATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL HYPOXIA; DRUG EFFECTS; DRUG SCREENING; EMULSION; HUMAN; METABOLISM; PANCREATIC NEOPLASMS; PILOT STUDY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; EMULSIONS; FEMALE; FLUOROCARBONS; HUMANS; MICE; MICE, SCID; NANOPARTICLES; PANCREATIC NEOPLASMS; PILOT PROJECTS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918532538     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.1903     Document Type: Article

References (39)

1. L. H. Gray, A. D. Conger, M. Ebert, S. Hornsey, and O. Scott, Concentration of oxygen dissolved in tissues at time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26, 638 (1953).
2. L. B. Harrison, M. Chadha, R. J. Hill, K. Hu, and D. Sasha, Impact of tumor hypoxia and anemia on radiation therapy outcomes. The Oncologist 7, 492 (2002).
3. D. M. Brizel, G. S. Sibley, L. R. Prosnitz, and R. L. Scher, Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. International Journal of Radiation Oncology. Biology. Physics 38, 285 (1997).
4. M. Höckel and P. Vaupel, Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 93, 266 (2001).
5. P. Vaupel and L. Harrison, Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. The oncologist 9, 4 (2004).
6. S. Rockwel, I. Dobrucki, I. T., E. Y. Kim, S. T. Marrison, and V. T. Vu, Hypoxia and radiation therapy: Past history, ongoing research, and future promise. Current Molecular Medicine 9, 442 (2009).
7. P. Vaupel, M. Höckel, and A. Mayer, Detection and characterization of tumor hypoxia using pO2 histography. Antioxidants and redox signaling 9, 1221 (2007).
8. 18F] fluoromisonidazole positron emission tomography before radiotherapy: Correlation with time to progression and survival. Clinical Cancer Research 14, 2623 (2008).
9. C. H. Chang, Hyperbaric oxygen and radiation therapy in the management of glioblastoma. National Cancer Institute Monograph 46, 163 (1977).
10. http://www.drugs.com/news/approval-not-recommended-rsr13-Adjunctivetherapy-brain-metastases-originating-breast-cancer-3500.html
11. C. Rose, R. Lustig, N. McIntosh, and B. Teicher, A clinical trial of fluosol DA 20% in advanced squamous cell carcinoma of the head and neck. International Journal of Radiation Oncology. Biology. Physics 12, 1325 (1986).
12. D. J. Chaplin, M. R. Horsman, and D. S. Aoki, Nicotinamide, fluosol DA and carbogen: A strategy to reoxygenate acutely and chronically hypoxic cells in vivo. British Journal of Cancer 63, 109 (1991).
13. S. Rockwell, M. Kelley, C. G. Irvin, and C. S. Hughes, Modulation of tumor oxygenation and radio sensitivity by a perfluorooctylbromide emulsion. Radiotherapy and Oncology 22, 92 (1991).
14. S. Reagan-Shaw, M. Nihal, and N. Ahmad, Dose translation from animal to human studies revisited. The FASEB Journal 22, 659 (2008).
15. D. M. Brizel, W. D. Hage, R. K. Dodge, and M. T. Munley, Hyperbaric oxygen improves tumor radiation response significantly more than carbogen/nicotinamide. Radiation Research 147, 715 (1997).
16. J. Sheehan, A. Ionescu, N. Pouratain, and D. K. Hamilton, Trans sodium crocetinate sensitizes glioblastoma multiforme tumors to radiation. J. Neurosurg. 108, 972 (2008).
17. M. E. Burkard and H. D. Van Liew, Oxygen transport to tissue by persistent bubbles: Theory and simulations. Journal of Applied Physiology 77, 2874 (1994).
18. H. D. Van Liew and M. E. Burkard. High oxygen partial pressure in tissue delivered by stabilized microbubbles, Oxygen Transport to Tissue XVIII, Springer, US (1997), pp. 395-401.
19. J. L. C. Johnson, M. C. Dolezal, A. Kerschen, T. O. Matsunaga, and E. C. Unger, In vitro comparison of dodecafluoropentane (DDFP), perfluorodecalin (PFD), and perfluoroctylbromide (PFOB) in the facilitation of oxygen exchange. Artif Cell Blood Substitutes 37, 156 (2009).
20. C. J. Koch, P. R. Oprysko, A. L. Shuman, W. T. Jenkins, G. Brandt, and S. M. Evans, Radiosensitization of hypoxic tumor cells by dodecafluoropentane: A gas-phase perfluorochemical emulsion. Cancer Research 62, 3626 (2002).
21. P. J. Loehrer, M. E. Powell, and H. R. Cardenes, A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J. Clin. Oncol. 26, 4506 (2008).
22. Q. Chang, I. Jurisica, T. Do, and D. W. Hedley, Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res. 15, 3110 (2011).
23. T. Arumugam, V. Ramachandran, K. F. Fournier, and H. Wang, Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Research 69, 5820 (2009).
24. M. Akada, T. Crnogorac-Jurcevic, and S. Lattimore, Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clinical cancer Research 11, 3094 (2005).
25. F. Marchesi, P. Monti, E. L. Biagio, A. Zerbi, A. Vecchi, L. Piemonti, A. Mantovani, and P. Allavena, Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Research 64, 8420 (2004).
26. G. Audi, The NUBASE Evaluation of Nuclear and Decay Properties. Nuclear Physics A (Atomic Mass Data Center) 729, 3 (2003).
27. C. Mandeville and H. Fulbright, The energies of the -rays from Sb122, Cd115, Ir192, Mn54, Zn65, and Co60. Physical Review 64, 265 (1943).
28. National Research Council (U.S.). Committee on Radiation Source Use and Replacement; National Research Council (U.S.). Nuclear and Radiation Studies Board. Radiation source use and replacement: Abbreviated version. National Academies Press, January (2008), p. 35.
29. M. H. Baba, M. Mohib-ul-Haq, and A. A. Khan, Dosimetric consistency of Co-60 teletherapy unit-A ten years study. International Journal of Health Sciences 7, 15 (2013).
30. S. Reagan-Shaw, M. Nihal, and N. Ahmad, Dose translation from animal to human studies revisited. The FASEB Journal 22, 659 (2008).
31. J. E. Moulder and B. L. Fish, Intermittent use of a perfluorochemical emulsion (fluosol®-DA 20%) and carbogen breathing with fractionated irradiation. International Journal of Radiation Oncology. Biology. Physics 15, 1193 (1988).
32. P. A. Grayburn, J. L. Weiss, T. C. Hack, E. Klodas, J. S. Raichlen, M. Vannan, A. L. Klein, D. W. Kitzman, S. G. Chrysant, J. L. Cohen, D. Abrahamson, E. Foster, J. E. Perez, G. P. Aurigemma, J. A. Panza, M. H. Picard, B. F. Byrd, D. S. Segar, S. A. Jacobson, D. J. Sahan, and A. N. DeMaria, Phase III multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (Albunex) as ultrasound contrast agents in patients with suboptimal echocardiograms. Journal of the American College of Cardiology 32, 230 (1998).
33. J.-M. Correas, A. R. Meuter, E. Singlas, D. R. Kessler, D. Worah, and S. C. Quay, Human pharmacokinetics of a perfluorocarbon ultrasound contrast agent evaluated with gas chromatography. Ultrasound in Medicine and Biology 27, 565 (2001).
34. J. Sheehan, J. Sherman, C. Cifarelli, J. Jagannathan, K. Dassoulas, C. Olson, J. Rainey, and S. Han, Effect of trans sodium crocetinate on brain tumor oxgenation: Laboratory investigation. Journal of Neurosurgery 111, 226 (2009).
35. J. P. Sheehan, A. Ionescu, N. Pouratian, D. K. Hamilton, D. Schlesinger, R. J. Oskouian, Jr, and C. Sansur, Trans sodium crocetinate: Functional neuroimaging studies in a hypoxic brain tumor: Laboratory investigation. Journal of Neurosurgery 115, 749 (2011).
36. Y. Ding, R. P. Mason, R. W. McColl, Q. Yuan, R. R. Hallac, R. D. Sims, and P. T. Weatherall, Simultaneous measurement of tissue oxygen level-dependent (TOLD) and blood oxygenation level-dependent (BOLD) effects in abdominal tissue oxygenation level studies. Journal of Magnetic Resonance Imaging 12, 661 (2000).
37. F. A. Howe, S. J. Barton, S. A. Cudlip, M. Stubbs, D. E. Saunders, M. Murphy, P. Wilkins, K. S. Opstad, V. L. Doyle, M. A. McLean, B. A. Bell, and J. R. Griffiths, Metabolic profiles of human brain tumors using quantitative in vivo 1 H magnetic resonance spectroscopy. Magnetic Resonance in Medicine 49, 223 (2003).
38. J. T. Leith, S. Cook, P. Chougule, P. Calabresi, L. Wahlberg, C. Lindquist, and M. Epsstein, Intrinsic and extrinsic characteristics of human tumors relevant to radiosurgery: Comparative cellular radiosensitivity and hypoxic percentages, Advances in Radiosurgery, Springer, Vienna (1994), pp. 18-27.
39. R. Stupp, W. P. Mason, M. J. Van Den Bent, M. Weller, B. Fisher, M. J. B. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer and R. O. Mirimanoff, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 352, 987 (2005).